Perspective Therapeutics, Inc.
CATX
$3.46
-$0.22-5.98%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -15.64% | -3.60% | 1.39% | 351.13% | 78.32% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -15.64% | -3.60% | 1.39% | 351.13% | 78.32% |
| Cost of Revenue | 87.50% | 90.56% | 120.04% | 904.62% | 639.69% |
| Gross Profit | -91.13% | -94.45% | -126.19% | -721.77% | -751.55% |
| SG&A Expenses | 47.90% | 40.92% | 26.34% | 36.63% | 26.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | 200.00% | 200.00% |
| Total Operating Expenses | 72.65% | 68.58% | 61.06% | 98.97% | 95.79% |
| Operating Income | -75.30% | -71.07% | -63.15% | -89.78% | -96.36% |
| Income Before Tax | -120.33% | -103.92% | -100.39% | -69.09% | -84.77% |
| Income Tax Expenses | -126.72% | -126.72% | 20.90% | 174.75% | 174.75% |
| Earnings from Continuing Operations | -83.11% | -67.99% | -108.97% | -204.16% | -287.35% |
| Earnings from Discontinued Operations | 106.58% | 93.18% | 88.87% | -58.45% | -124.11% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -60.89% | -45.79% | -70.46% | -154.12% | -213.73% |
| EBIT | -75.30% | -71.07% | -63.15% | -89.78% | -96.36% |
| EBITDA | -117.37% | -116.25% | -111.92% | -88.77% | -95.39% |
| EPS Basic | 20.91% | 36.16% | 27.43% | -49.85% | -79.88% |
| Normalized Basic EPS | 12.50% | 33.27% | 41.69% | 8.95% | -7.37% |
| EPS Diluted | -13.26% | 5.99% | -6.96% | -49.85% | -79.88% |
| Normalized Diluted EPS | 12.50% | 33.27% | 41.69% | 8.95% | -7.37% |
| Average Basic Shares Outstanding | 67.17% | 109.84% | 140.75% | 130.75% | 117.35% |
| Average Diluted Shares Outstanding | 67.17% | 109.84% | 140.75% | 130.75% | 117.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |